
NCPA Announces Second Phase of Program with CPESN and Bristol Myers Squibb Enlisting Pharmacists in the Fight Against Stroke and Heart Disease
Key Takeaways
- Phase 1 across 25 pharmacies in six Stroke Belt states produced nearly 10,000 at-risk identifications, >11,000 patient encounters, and >20,000 interventions within six months.
- Service lines included stroke risk assessment, atrial fibrillation detection, transitions-of-care support, and screening for health-related social needs such as food, housing, and transportation insecurity.
Expanded use of pharmacists could result in millions of dollars and thousands of patients saved, initial results suggest
ALEXANDRIA, Va. (Nov. 17, 2026) – The National Community Pharmacists Association in collaboration with CPESN® USA and Bristol Myers Squibb today announced that a pioneering research project enlisting pharmacists and their teams to screen for signs of heart disease and stroke will be tripled in scope because of the dramatic results produced by the first phase.
“The results of the first phase were extremely encouraging,” said B. Douglas Hoey, CEO of NCPA.“Pharmacists in the program intervened on behalf of thousands of patients who would not have known otherwise that they were at risk. Those pharmacists very likely saved many lives and prevented serious risks from becoming catastrophic health events.”
The program is a collaboration between the NCPA’s Innovation Center and CPESN Community Health, and is supported by Bristol Myers Squibb. In the first phase, data was collected over six months from 25 pharmacies in six states (Alabama, Arkansas, Kentucky, Louisiana, Mississippi, and Missouri) known as the “Stroke Belt” because of its high prevalence of cardiovascular disease. In Phase 2, which will also run for six months, up to 50 more pharmacies will be added across six more states (Florida, Idaho, Nevada, North Carolina, Oregon, and Texas). The goal is to screen an additional 15,000 patients for cardiovascular risk, and to track the health outcomes for patients identified at risk in Phase 1.
“Cardiovascular disease is still the leading cause of death in the U.S., and too often it goes unnoticed until it becomes an emergency,” said Al Reba, senior vice president of immunology and cardiovascular commercialization at Bristol Myers Squibb. “Phase 1 results indicate that pharmacy teams can find that risk early in communities where access to care is limited and connect people to the help they need before a problem becomes more serious. We’re looking forward to learning even more in Phase 2 about how this program can help people in rural areas.”
“CPESN pharmacies offer our patients so much more than pills in a bottle. Every day, community pharmacists are delivering valuable clinical services and improving the health of the patients they serve. This project builds on that work and creates even more opportunities for pharmacies to make a meaningful difference,” said Tripp Logan, PharmD, CPESN Community Health lead luminary and owner of L&S Pharmacy. “We’re very thankful for NCPA’s leadership and Bristol Myers Squibb’s continued support of this initiative. Our communities are healthier because of it.”
Under the program, pharmacists screen and counsel patients, and pharmacy technicians, cross-trained as community health workers, engage at-risk patients and, if necessary, connect them with social services they may need to get adequate health care. They can also refer patients to agencies that provide transportation, housing assistance, and even insurance coverage.
According to the data from
Among the patients screened for stroke risk, roughly 2,700 received education from pharmacists, and another 267 were referred to a physician for follow-up care. Pharmacy staff identified 400 patients with abnormal heart rhythm. Eighty-one percent of them were referred to a physician. Fifteen percent didn’t have a primary physician, so pharmacy staff found one for them and made a referral. That intervention alone is estimated to have saved $35,000 for each patient with undetected atrial fibrillation.
“In many rural areas, the pharmacist is the most accessible health care provider,” said Hoey. “Those pharmacists are educated and trained to provide life-saving clinical services like these, but our health care system does not currently take full advantage of the value they offer. This groundbreaking program shows that pharmacists are an important element of the health care infrastructure, and that there is much more they can do to detect and improve public health.”
“We are committed to population health and closing the gaps that keep people from getting the care they need,” said Andrew Whitehead, vice president, head of population health at Bristol Myers Squibb.“Independent community pharmacies are trusted and accessible, and this program equips their teams to connect patients to care and to address everyday barriers like transportation. We’re proud to support Phase 2 as it reaches people in more communities, and we look forward to sharing the results in mid-2027.”
Related to this article








